William Mack & Associates’s Bioventus BVS Stock Holding History

William Mack & Associates’s Portfolio BVS Stock Details BVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$11.5K	Buy	+841	New	+$11.1K	﹤0.01%	389

Other funds holding BVS

Essex Woodlands Management The Woodlands, Texas $323M AUM 25.39% 1-Year Est. Return

Nantahala Capital Management New Canaan, Connecticut $3.16B AUM 31.44% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

American Century Companies Kansas City, Missouri $229B AUM 33.35% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Royce & Associates New York $11B AUM 39.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Hillsdale Investment Management Toronto, Ontario, Canada $4.42B AUM 54.57% 1-Year Est. Return

William Mack & Associates's BVS Position: Q3 2026 in Review

William Mack & Associates opened a new position in Bioventus (BVS) in Q3 2026: 841 shares worth $11.5K. The stake represents ﹤0.01% of the portfolio and ranks #389 among its holdings.

127 funds tracked by Wall St. Rank hold BVS as of Q3 2026.

William Mack & Associates held 841 shares of Bioventus worth $11.5K as of Q3 2026.
Bioventus was a new William Mack & Associates position in Q3 2026.
Bioventus made up ﹤0.01% of William Mack & Associates's portfolio in Q3 2026, its #389 holding.
127 funds tracked by Wall St. Rank held Bioventus as of Q3 2026.

Based on William Mack & Associates's 13F filing for Q3 2026, filed 27 Oct 2026.